Published in Infect Immun on June 01, 2001
Adjuvanted intranasal Norwalk virus-like particle vaccine elicits antibodies and antibody-secreting cells that express homing receptors for mucosal and peripheral lymphoid tissues. J Infect Dis (2010) 2.64
Immunology of gut mucosal vaccines. Immunol Rev (2011) 1.59
Characterization of a mutant Escherichia coli heat-labile toxin, LT(R192G/L211A), as a safe and effective oral adjuvant. Clin Vaccine Immunol (2011) 1.51
Clearance of Helicobacter pylori Infection and Resolution of Postimmunization Gastritis in a Kinetic Study of Prophylactically Immunized Mice. Infect Immun (2002) 1.37
Protection against aerosolized Yersinia pestis challenge following homologous and heterologous prime-boost with recombinant plague antigens. Infect Immun (2005) 1.14
Vaccinating against Helicobacter pylori infection. Nat Rev Gastroenterol Hepatol (2011) 1.14
Protection against experimental Helicobacter pylori infection after immunization with inactivated H. pylori whole-cell vaccines. Infect Immun (2002) 1.12
Toward the development of a stable, freeze-dried formulation of Helicobacter pylori killed whole cell vaccine adjuvanted with a novel mutant of Escherichia coli heat-labile toxin. Vaccine (2009) 1.11
Protective immunity against Helicobacter is characterized by a unique transcriptional signature. Proc Natl Acad Sci U S A (2003) 1.10
Therapeutic vaccination against Helicobacter pylori in the beagle dog experimental model: safety, immunogenicity, and efficacy. Infect Immun (2004) 1.06
Colonization of C57BL/6J and BALB/c wild-type and knockout mice with Helicobacter pylori: effect of vaccination and implications for innate and acquired immunity. Infect Immun (2003) 1.04
Generation of Helicobacter pylori ghosts by PhiX protein E-mediated inactivation and their evaluation as vaccine candidates. Infect Immun (2003) 1.01
A double mutant heat-labile toxin from Escherichia coli, LT(R192G/L211A), is an effective mucosal adjuvant for vaccination against Helicobacter pylori infection. Infect Immun (2013) 0.98
Safety and immunogenicity of a single oral dose of recombinant double mutant heat-labile toxin derived from enterotoxigenic Escherichia coli. Clin Vaccine Immunol (2013) 0.97
Transfer of antigen-pulsed dendritic cells induces specific T-Cell proliferation and a therapeutic effect against long-term Helicobacter pylori infection in mice. Infect Immun (2006) 0.95
Toxin-mediated effects on the innate mucosal defenses: implications for enteric vaccines. Infect Immun (2009) 0.95
Who's Winning the War? Molecular Mechanisms of Antibiotic Resistance in Helicobacter pylori. Curr Drug ther (2008) 0.92
Effects of a Th1- versus a Th2-biased immune response in protection against Helicobacter pylori challenge in mice. Microb Pathog (2007) 0.90
Randomized clinical trial assessing the safety and immunogenicity of oral microencapsulated enterotoxigenic Escherichia coli surface antigen 6 with or without heat-labile enterotoxin with mutation R192G. Clin Vaccine Immunol (2008) 0.90
Systemic Th1 immunization of mice against Helicobacter pylori infection with CpG oligodeoxynucleotides as adjuvants does not protect from infection but enhances gastritis. Infect Immun (2004) 0.88
The adjuvant double mutant Escherichia coli heat labile toxin enhances IL-17A production in human T cells specific for bacterial vaccine antigens. PLoS One (2012) 0.88
Evaluation of combinatorial vaccines against anthrax and plague in a murine model. Vaccine (2007) 0.86
A study of recombinant protective H.pylori antigens. World J Gastroenterol (2002) 0.84
Construction of recombinant attenuated Salmonella typhimurium DNA vaccine expressing H pylori ureB and IL-2. World J Gastroenterol (2007) 0.84
Helicobacter pylori L-form and patients with chronic gastritis. World J Gastroenterol (2004) 0.83
Role of Helicobacter pylori infection in gastric carcinogenesis: Current knowledge and future directions. World J Gastroenterol (2015) 0.83
Cholera-like enterotoxins and Regulatory T cells. Toxins (Basel) (2010) 0.82
Construction and characterization of bivalent vaccine candidate expressing HspA and M(r)18,000 OMP from Helicobacter pylori. World J Gastroenterol (2003) 0.81
Human immune responses to H. pylori HLA Class II epitopes identified by immunoinformatic methods. PLoS One (2014) 0.80
Evaluation in mice of a conjugate vaccine for cholera made from Vibrio cholerae O1 (Ogawa) O-specific polysaccharide. PLoS Negl Trop Dis (2014) 0.80
Immunological activation following transcutaneous delivery of HR-gp100 protein. Vaccine (2007) 0.80
Construction of expression systems for flaA and flaB genes of Helicobacter pylori and determination of immunoreactivity and antigenicity of recombinant proteins. World J Gastroenterol (2003) 0.80
Vaccinating against Helicobacter pylori in the developing world. Gut Microbes (2013) 0.80
L-forms of H. pylori. World J Gastroenterol (2003) 0.80
Construction of hpaA gene from a clinical isolate of Helicobacter pylori and identification of fusion protein. World J Gastroenterol (2003) 0.80
Protective efficacy of recombinant urease B and aluminum hydroxide against Helicobacter pylori infection in a mouse model. FEMS Immunol Med Microbiol (2010) 0.78
Helicobacter pylori vaccination: is there a path to protection? World J Gastroenterol (2014) 0.78
Unexpected modulation of recall B and T cell responses after immunization with rotavirus-like particles in the presence of LT-R192G. Toxins (Basel) (2010) 0.76
Identification of Helicobacter pylori and the evolution of an efficacious childhood vaccine to protect against gastritis and peptic ulcer disease. Pediatr Res (2016) 0.75
Leptin, CD4(+) T(reg) and the prospects for vaccination against H. pylori infection. Front Immunol (2012) 0.75
Helicobacter pylori infection and the risk of gastric carcinoma. N Engl J Med (1991) 23.89
Helicobacter pylori infection and gastric carcinoma among Japanese Americans in Hawaii. N Engl J Med (1991) 11.98
Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori. Lancet (1993) 11.38
Association between infection with Helicobacter pylori and risk of gastric cancer: evidence from a prospective investigation. BMJ (1991) 9.88
Cure of duodenal ulcer associated with eradication of Helicobacter pylori. Lancet (1990) 9.49
NIH Consensus Conference. Helicobacter pylori in peptic ulcer disease. NIH Consensus Development Panel on Helicobacter pylori in Peptic Ulcer Disease. JAMA (1994) 8.57
Isolation and characterization of homogeneous heat-labile enterotoxins with high specific activity from Escherichia coli cultures. Infect Immun (1979) 7.21
Mucosal IgA recognition of Helicobacter pylori 120 kDa protein, peptic ulceration, and gastric pathology. Lancet (1991) 6.73
Effect of treatment of Helicobacter pylori infection on the long-term recurrence of gastric or duodenal ulcer. A randomized, controlled study. Ann Intern Med (1992) 6.64
Prospective double-blind trial of duodenal ulcer relapse after eradication of Campylobacter pylori. Lancet (1989) 6.58
Development of a mouse model of Helicobacter pylori infection that mimics human disease. Science (1995) 5.73
Diagnostic value of decreasing IgG, IgA, and IgM antibody titres after eradication of Helicobacter pylori. Lancet (1992) 4.54
Lymphocytes in the human gastric mucosa during Helicobacter pylori have a T helper cell 1 phenotype. Gastroenterology (1998) 4.12
Duodenal ulcer healing by eradication of Helicobacter pylori without anti-acid treatment: randomised controlled trial. Lancet (1994) 4.07
Many pulmonary pathogenic bacteria bind specifically to the carbohydrate sequence GalNAc beta 1-4Gal found in some glycolipids. Proc Natl Acad Sci U S A (1988) 3.83
Dissociation of Escherichia coli heat-labile enterotoxin adjuvanticity from ADP-ribosyltransferase activity. Infect Immun (1995) 3.22
Oral immunization with urease and Escherichia coli heat-labile enterotoxin is safe and immunogenic in Helicobacter pylori-infected adults. Gastroenterology (1999) 2.72
Immunization of mice with urease vaccine affords protection against Helicobacter pylori infection in the absence of antibodies and is mediated by MHC class II-restricted responses. J Exp Med (1998) 2.70
Interferon gamma and interleukin 4 secreting cells in the gastric antrum in Helicobacter pylori positive and negative gastritis. Gut (1995) 2.52
Pseudomonas aeruginosa and Pseudomonas cepacia isolated from cystic fibrosis patients bind specifically to gangliotetraosylceramide (asialo GM1) and gangliotriaosylceramide (asialo GM2). Arch Biochem Biophys (1988) 2.49
Protection of germ-free mice from infection by Helicobacter felis after active oral or passive IgA immunization. Vaccine (1993) 2.36
Immunization of BALB/c mice against Helicobacter felis infection with Helicobacter pylori urease. Gastroenterology (1994) 2.35
Helicobacter pylori and gastric carcinoma. Serum antibody prevalence in populations with contrasting cancer risks. Cancer (1990) 2.32
Immunogenicity in humans of a recombinant bacterial antigen delivered in a transgenic potato. Nat Med (1998) 2.20
A nontoxic mutant of cholera toxin elicits Th2-type responses for enhanced mucosal immunity. Proc Natl Acad Sci U S A (1997) 2.07
Cytokine production patterns and lymphoproliferative responses in volunteers orally immunized with attenuated vaccine strains of Salmonella typhi. J Infect Dis (1994) 2.03
The neutrophil-activating protein (HP-NAP) of Helicobacter pylori is a protective antigen and a major virulence factor. J Exp Med (2000) 2.02
The GroES homolog of Helicobacter pylori confers protective immunity against mucosal infection in mice. Proc Natl Acad Sci U S A (1995) 1.99
Oral immunization with recombinant Helicobacter pylori urease induces secretory IgA antibodies and protects mice from challenge with Helicobacter felis. J Infect Dis (1995) 1.97
Oral immunization with Helicobacter pylori urease B subunit as a treatment against Helicobacter infection in mice. Gastroenterology (1995) 1.77
Recombinant antigens prepared from the urease subunits of Helicobacter spp.: evidence of protection in a mouse model of gastric infection. Infect Immun (1994) 1.77
Mechanisms for mucosal immunogenicity and adjuvancy of Escherichia coli labile enterotoxin. J Infect Dis (1996) 1.68
Serum neutralizing antibody response to the vacuolating cytotoxin of Helicobacter pylori. J Clin Invest (1992) 1.66
The epidemiology of Helicobacter pylori in Peruvian children between 6 and 30 months of age. Am J Gastroenterol (1994) 1.62
Therapeutic intragastric vaccination against Helicobacter pylori in mice eradicates an otherwise chronic infection and confers protection against reinfection. Infect Immun (1997) 1.57
Salmonella typhi flagella are potent inducers of proinflammatory cytokine secretion by human monocytes. Infect Immun (1999) 1.55
Rectal and intranasal immunizations with recombinant urease induce distinct local and serum immune responses in mice and protect against Helicobacter pylori infection. Infect Immun (1998) 1.54
Differential stimulation of interleukin-12 (IL-12) and IL-10 by live and killed Helicobacter pylori in vitro and association of IL-12 production with gamma interferon-producing T cells in the human gastric mucosa. Infect Immun (1997) 1.52
Successful immunization against gastric infection with Helicobacter species: use of a cholera toxin B-subunit-whole-cell vaccine. Infect Immun (1994) 1.51
Pilot study of phoP/phoQ-deleted Salmonella enterica serovar typhimurium expressing Helicobacter pylori urease in adult volunteers. Infect Immun (2000) 1.44
Systemic immunization with urease protects mice against Helicobacter pylori infection. Vaccine (1998) 1.42
Safety and immunogenicity of phoP/phoQ-deleted Salmonella typhi expressing Helicobacter pylori urease in adult volunteers. Vaccine (1999) 1.41
Gastric T lymphocyte responses to Helicobacter pylori in patients with H pylori colonisation. Gut (1994) 1.40
Helicobacter pylori reinfection with identical organisms: transmission by the patients' spouses. Gut (1995) 1.36
Catalase, a novel antigen for Helicobacter pylori vaccination. Infect Immun (1997) 1.34
Helicobacter pylori in the pediatric patient. Gastroenterol Clin North Am (1993) 1.28
Therapeutic immunisation against Helicobacter infection. Lancet (1994) 1.21
Urease-specific monoclonal antibodies prevent Helicobacter felis infection in mice. Infect Immun (1995) 1.20
Immunization of BALB/c mice with Helicobacter urease B induces a T helper 2 response absent in Helicobacter infection. Gastroenterology (1998) 1.20
Attenuated deltaguaBA Salmonella typhi vaccine strain CVD 915 as a live vector utilizing prokaryotic or eukaryotic expression systems to deliver foreign antigens and elicit immune responses. Clin Immunol (1999) 1.20
Immune response to an 18-kilodalton outer membrane antigen identifies lipoprotein 20 as a Helicobacter pylori vaccine candidate. Infect Immun (2000) 1.15
High incidence of Campylobacter-like organisms in endoscopic biopsies from patients with gastritis, with or without peptic ulcer. Digestion (1987) 1.14
Low rates of Helicobacter pylori reinfection in children. Gastroenterology (1999) 1.08
Therapeutic oral vaccination induces mucosal immune response sufficient to eliminate long-term Helicobacter pylori infection. Microbiol Immunol (2000) 1.06
Role of trypsin-like cleavage at arginine 192 in the enzymatic and cytotonic activities of Escherichia coli heat-labile enterotoxin. Infect Immun (1994) 1.05
Recurrence of Helicobacter pylori infection after successful eradication: nature and possible causes. Dig Dis Sci (1997) 1.02
Immunization with recombinant Helicobacter pylori urease decreases colonization levels following experimental infection of rhesus monkeys. Vaccine (1999) 1.00
Vaccination of gnotobiotic piglets against Helicobacter pylori. J Infect Dis (1998) 0.97
Urease-based mucosal immunization against Helicobacter heilmannii infection induces corpus atrophy in mice. Infect Immun (1999) 0.95
The association of Helicobacter pylori with gastric cancer and preneoplastic gastric lesions in Chiapas, Mexico. Cancer (1993) 0.94
Suppressive effects of DNA vaccines encoding heat shock protein on Helicobacter pylori-induced gastritis in mice. Biochem Biophys Res Commun (2000) 0.91
Enterotoxic effect of the vacuolating toxin produced by Helicobacter pylori in Caco-2 cells. J Infect Dis (1998) 0.85
What is the role for vaccination in Helicobacter pylori? Gastroenterology (1997) 0.84
Helicobacter pylori vaccine development and use: a cost-effectiveness analysis using the Institute of Medicine Methodology. Helicobacter (1999) 0.82
Mutants of Escherichia coli heat-labile enterotoxin as an adjuvant for nasal influenza vaccine. Vaccine (1998) 0.82
A critical appraisal of 98.6 degrees F, the upper limit of the normal body temperature, and other legacies of Carl Reinhold August Wunderlich. JAMA (1992) 6.88
Determinants of HIV-1 shedding in the genital tract of women. Lancet (2001) 5.10
Pathophysiology of Campylobacter enteritis. Microbiol Rev (1986) 4.94
Role of the eaeA gene in experimental enteropathogenic Escherichia coli infection. J Clin Invest (1993) 4.53
Vibrio cholerae produces a second enterotoxin, which affects intestinal tight junctions. Proc Natl Acad Sci U S A (1991) 3.43
Association of Aeromonas sobria with human infection. J Clin Microbiol (1981) 3.17
Economisation of vaccination against Haemophilus influenzae type b: a randomised trial of immunogenicity of fractional-dose and two-dose regimens. Lancet (1998) 2.98
Reversible expression of flagella in Campylobacter jejuni. Infect Immun (1985) 2.92
Identification and characterization of two Campylobacter jejuni adhesins for cellular and mucous substrates. Infect Immun (1986) 2.85
The role of macrophages in the acute-phase response: SAA inducer is closely related to lymphocyte activating factor and endogenous pyrogen. Cell Immunol (1981) 2.60
The significance of hematologic abnormalities in patients with tuberculosis. Arch Intern Med (1970) 2.45
Safety of live oral Salmonella typhi vaccine strains with deletions in htrA and aroC aroD and immune response in humans. Infect Immun (1997) 2.44
Experimental human infections with Giardia lamblia. J Infect Dis (1987) 2.42
Phase II safety and immunogenicity study of live chikungunya virus vaccine TSI-GSD-218. Am J Trop Med Hyg (2000) 2.39
Experimental non-O group 1 Vibrio cholerae gastroenteritis in humans. J Clin Invest (1990) 2.33
Reduction of transmission of shigellosis by control of houseflies (Musca domestica) Lancet (1991) 2.30
Vibrio cholerae O1 can assume a chlorine-resistant rugose survival form that is virulent for humans. J Infect Dis (1996) 2.17
Cytokine production patterns and lymphoproliferative responses in volunteers orally immunized with attenuated vaccine strains of Salmonella typhi. J Infect Dis (1994) 2.03
Simple adult rabbit model for Campylobacter jejuni enteritis. Infect Immun (1983) 2.02
Regulation of human peripheral blood monocyte DR antigen expression in vitro by lymphokines and recombinant interferons. J Clin Invest (1984) 2.00
Synergistic effect of bacteroides, Clostridium, Fusobacterium, anaerobic cocci, and aerobic bacteria on mortality and induction of subcutaneous abscesses in mice. J Infect Dis (1984) 1.94
Role of endotoxemia in cardiovascular dysfunction and mortality. Escherichia coli and Staphylococcus aureus challenges in a canine model of human septic shock. J Clin Invest (1989) 1.87
Differentiation between African populations is evidenced by the diversity of alleles and haplotypes of HLA class I loci. Tissue Antigens (2004) 1.86
Significance of flagella in colonization resistance of rabbits immunized with Campylobacter spp. Infect Immun (1991) 1.85
A modified Shigella volunteer challenge model in which the inoculum is administered with bicarbonate buffer: clinical experience and implications for Shigella infectivity. Vaccine (1995) 1.74
Role of Vibrio cholerae neuraminidase in the function of cholera toxin. Infect Immun (1992) 1.72
Clinical acceptability and immunogenicity of CVD 908 Salmonella typhi vaccine strain. Vaccine (1992) 1.69
Seroprevalence of Helicobacter pylori in Seventh-Day Adventists and other groups in Maryland. Lack of association with diet. Arch Intern Med (1990) 1.68
Efficacy trial of single-dose live oral cholera vaccine CVD 103-HgR in North Jakarta, Indonesia, a cholera-endemic area. Vaccine (2000) 1.67
Mucosal immunity induced by enhance-potency inactivated and oral polio vaccines. J Infect Dis (1991) 1.66
Optimization of plasmid maintenance in the attenuated live vector vaccine strain Salmonella typhi CVD 908-htrA. Infect Immun (1999) 1.66
Specific immunoglobulin A-secreting cells in peripheral blood of humans following oral immunization with a bivalent Salmonella typhi-Shigella sonnei vaccine or infection by pathogenic S. sonnei. Infect Immun (1990) 1.64
Phase 2 clinical trial of attenuated Salmonella enterica serovar typhi oral live vector vaccine CVD 908-htrA in U.S. volunteers. Infect Immun (2000) 1.63
Biphasic culture system for rapid Campylobacter cultivation. Appl Environ Microbiol (1983) 1.60
Seroprevalence of Helicobacter pylori in Chile: vegetables may serve as one route of transmission. J Infect Dis (1993) 1.59
An analysis of the quantitative relationship between oral temperature and severity of illness in experimental shigellosis. J Infect Dis (1992) 1.55
Salmonella typhi flagella are potent inducers of proinflammatory cytokine secretion by human monocytes. Infect Immun (1999) 1.55
Role of EspB in experimental human enteropathogenic Escherichia coli infection. Infect Immun (2000) 1.47
Haemophilus influenzae disease in the White Mountain Apaches: molecular epidemiology of a high risk population. Pediatr Infect Dis (1985) 1.45
Epitope-specific immune responses to rotavirus vaccination. Gastroenterology (1987) 1.44
Shigella flexneri 2a strain CVD 1207, with specific deletions in virG, sen, set, and guaBA, is highly attenuated in humans. Infect Immun (2000) 1.44
Salmonella typhi vaccine strain CVD 908 expressing the circumsporozoite protein of Plasmodium falciparum: strain construction and safety and immunogenicity in humans. J Infect Dis (1994) 1.43
Immunoprophylaxis of RSV infection: advancing from RSV-IGIV to palivizumab and motavizumab. Curr Top Microbiol Immunol (2008) 1.42
Intestinal mucus gel and secretory antibody are barriers to Campylobacter jejuni adherence to INT 407 cells. Infect Immun (1987) 1.42
Safety, immunogenicity, and excretion pattern of single-dose live oral cholera vaccine CVD 103-HgR in Peruvian adults of high and low socioeconomic levels. Infect Immun (1993) 1.40
Evaluation of the safety, immunogenicity, and efficacy in healthy adults of four doses of live oral hybrid Escherichia coli-Shigella flexneri 2a vaccine strain EcSf2a-2. Vaccine (1995) 1.38
Large scale, postlicensure, selective vaccination of Chilean infants with PRP-T conjugate vaccine: practicality and effectiveness in preventing invasive Haemophilus influenzae type b infections. Pediatr Infect Dis J (1996) 1.38
Differential expression of Vibrio vulnificus capsular polysaccharide. Infect Immun (1999) 1.36
Safety and immunogenicity in North Americans of a single dose of live oral cholera vaccine CVD 103-HgR: results of a randomized, placebo-controlled, double-blind crossover trial. Infect Immun (1992) 1.35
Host-Salmonella interaction: human trials. Microbes Infect (2001) 1.35
Effect of small bowel bacterial overgrowth on the immunogenicity of single-dose live oral cholera vaccine CVD 103-HgR. J Infect Dis (1999) 1.35
Pyrogenicity of granulocyte lysosomes. Am J Physiol (1966) 1.33
The role of interleukin 1 in acute phase serum amyloid A (SAA) and serum amyloid P (SAP) biosynthesis. Ann N Y Acad Sci (1982) 1.33
In vivo characterization of the murine intranasal model for assessing the immunogenicity of attenuated Salmonella enterica serovar Typhi strains as live mucosal vaccines and as live vectors. Infect Immun (2000) 1.32
Safety, immunogenicity, and transmissibility in humans of CVD 1203, a live oral Shigella flexneri 2a vaccine candidate attenuated by deletions in aroA and virG. Infect Immun (1996) 1.32
Detection and quantitation of human immunodeficiency virus type 1 in the female genital tract. The Division of AIDS Treatment Research Initiative 009 Study Group. J Clin Microbiol (2000) 1.31
Oral administration of human serum immunoglobulin in immunodeficient patients with viral gastroenteritis. A pharmacokinetic and functional analysis. J Clin Invest (1985) 1.31
Goldfish, Carassius auratus, a novel animal model for the study of Mycobacterium marinum pathogenesis. Infect Immun (1998) 1.28
Long-term persistence of sterile immunity in a volunteer immunized with X-irradiated Plasmodium falciparum sporozoites. J Infect Dis (1993) 1.28
Novel mechanism for Trypanosoma cruzi-induced suppression of human lymphocytes. Inhibition of IL-2 receptor expression. J Immunol (1988) 1.26
Safety and immunogenicity of a prototype oral whole-cell killed Campylobacter vaccine administered with a mucosal adjuvant in non-human primates. Vaccine (1995) 1.25
Mucosal and systemic immunity to Campylobacter jejuni in rabbits after gastric inoculation. Infect Immun (1988) 1.24
Safety and immunogenicity of increasing doses of a Clostridium difficile toxoid vaccine administered to healthy adults. Infect Immun (2001) 1.23
Validation of a volunteer model of cholera with frozen bacteria as the challenge. Infect Immun (1998) 1.23
Antibiotic and clavulanic acid treatment of subcutaneous abscesses caused by Bacteroides fragilis alone or in combination with aerobic bacteria. J Infect Dis (1983) 1.22
Factors influencing secondary vibriocidal immune responses: relevance for understanding immunity to cholera. Infect Immun (1996) 1.21
Serum cytokine profiles in experimental human malaria. Relationship to protection and disease course after challenge. J Clin Invest (1992) 1.21
Attenuated deltaguaBA Salmonella typhi vaccine strain CVD 915 as a live vector utilizing prokaryotic or eukaryotic expression systems to deliver foreign antigens and elicit immune responses. Clin Immunol (1999) 1.20
Pathogenicity of anaerobic gram-positive cocci. Infect Immun (1984) 1.19
A live attenuated dengue-1 vaccine candidate (45AZ5) passaged in primary dog kidney cell culture is attenuated and immunogenic for humans. J Infect Dis (1994) 1.19
Campylobacter fetus ss. Jejuni, a newly recognized enteric pathogen: morphology and intestinal colonization. Scan Electron Microsc (1981) 1.18
The relationship between Fusobacterium species and other flora in mixed infection. J Med Microbiol (1986) 1.18
Inhibition of lethality in endotoxin-challenged mice treated with zinc chloride. Infect Immun (1976) 1.17
Killed Campylobacter elicits immune response and protection when administered with an oral adjuvant. Vaccine (1993) 1.17
Release of tumor necrosis factor alpha in response to Vibrio vulnificus capsular polysaccharide in in vivo and in vitro models. Infect Immun (1997) 1.15
A voluntary serosurvey and behavioral risk assessment for human immunodeficiency virus infection among college students. Sex Transm Dis (1992) 1.15
A human challenge model for dengue infection reveals a possible protective role for sustained interferon gamma levels during the acute phase of illness. Vaccine (2011) 1.15
Safety and immune responses to attenuated Salmonella enterica serovar typhi oral live vector vaccines expressing tetanus toxin fragment C. Clin Immunol (2000) 1.14
Characteristics of an epidermal cell thymocyte-activating factor (ETAF) produced by human epidermal cells and a human squamous cell carcinoma cell line. J Invest Dermatol (1983) 1.12
Potent immunoregulatory effects of Salmonella typhi flagella on antigenic stimulation of human peripheral blood mononuclear cells. Infect Immun (1999) 1.12
Recovery of aerobic and anaerobic bacteria from irradiated mice. Infect Immun (1984) 1.12